In a letter to HRSA, ACH urged the agency to prohibit Eli Lilly from requiring claims-level data to access 340B drug pricing. This unilateral requirement acts as an unauthorized audit and imposes severe administrative burden on community health centers that are already facing unprecedented fiscal strain. The change threatens critical funding used to deliver care to millions of rural and underserved patients across the nation.